Literature DB >> 12391944

Economic evaluation of antineoplasic chemotherapy administered at home or in hospitals.

Raphaël Remonnay1, Yves Devaux, Franck Chauvin, Eric Dubost, Marie Odile Carrère.   

Abstract

OBJECTIVES: Comparative economic evaluations of chemotherapy administered in hospital day-care units or in the home are relatively scarce. Furthermore, most existing evaluations do not include methodologic studies. This study seeks to compare the costs of anticancer chemotherapy with hospital at-home care versus a hospital day-care unit in the Rhône-Alpes region of France.
METHODS: This study is based on a randomized controlled crossover trial that included 42 patients, to whom chemotherapy courses were alternatively given in both settings. All cost categories were taken into account according to microcosting methods. A detailed assessment was performed on coordination and health care in both structures (marginal costs and average costs), from the viewpoint of society.
RESULTS: The marginal cost for one chemotherapy administration was significantly higher with hospital at-home care than in the hospital day-care unit ($232.5 vs. $157, p < .0001). Conversely, the average cost was significantly lower with home care than at the hospital ($252.6 vs. $277.3, p = .0002).
CONCLUSIONS: The results show that the interest of developing home care in anticancer chemotherapy is questionable regarding costs. In the French healthcare system, where there is a surplus of hospital beds, marginal costs seem to be more relevant indicators in most cases than average costs.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12391944

Source DB:  PubMed          Journal:  Int J Technol Assess Health Care        ISSN: 0266-4623            Impact factor:   2.188


  3 in total

1.  Home care--a safe and attractive alternative to inpatient administration of intensive chemotherapies.

Authors:  François Lüthi; Nadia Fucina; Nathalie Divorne; Brigitte Santos-Eggimann; Christine Currat-Zweifel; Patricia Rollier; Jean-Blaise Wasserfallen; Nicolas Ketterer; Serge Leyvraz
Journal:  Support Care Cancer       Date:  2011-03-08       Impact factor: 3.603

2.  Is community treatment best? a randomised trial comparing delivery of cancer treatment in the hospital, home and GP surgery.

Authors:  P G Corrie; A M Moody; G Armstrong; S Nolasco; S-H Lao-Sirieix; L Bavister; A T Prevost; R Parker; R Sabes-Figuera; P McCrone; H Balsdon; K McKinnon; A Hounsell; B O'Sullivan; S Barclay
Journal:  Br J Cancer       Date:  2013-08-29       Impact factor: 7.640

Review 3.  Randomised trials comparing different healthcare settings: an exploratory review of the impact of pre-trial preferences on participation, and discussion of other methodological challenges.

Authors:  Mark S Corbett; Judith Watson; Alison Eastwood
Journal:  BMC Health Serv Res       Date:  2016-10-19       Impact factor: 2.655

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.